Novel Inhibitors of the Gardos Channel for the Treatment of Sickle Cell Disease
摘要:
Sickle cell disease (SCD) is a hereditary condition characterized by deformation of red blood cells (RBCs). This phenomenon is due to the presence of abnormal hemoglobin that polymerizes upon deoxygenation. This effect is exacerbated when dehydrated RBCs experience a loss of both water and potassium salts. One critical pathway for the regulation of potassium efflux from RBCs is the Gardos channel, a calcium-activated potassium channel. This paper describes the synthesis and biological evaluation of a series of potent inhibitors of the Gardos channel. The goal was to identify compounds that were potent and selective inhibitors of the channel but had improved pharmacokinetic properties compared to 1, Clotrimazole. Several triarylamides such as 10 and 21 were potent inhibitors of the Gardos channel (IC50 of < 10 nM) and active in a mouse model of SCD. Compound 21 (ICA-17043) was advanced into phase 3 clinical trials for SCD.
The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for the IK1 channel and greater stability relative to non-fluorine substituted homologues.
The use of novel inhibitors of potassium flux is disclosed for the treatment of inflammatory processes, such as multiple sclerosis, insulin-dependent (type I) diabetes mellitus, rheumatoid arthritis, peripheral neuritis and pulmonary hypertension. The compounds are also of use in treating and preventing stroke. These inhibitors have a high specificity for the IK1 channel and greater stability relative to non-fluorine substituted homologues.
Direct Amination of α-Triaryl Alcohols via Vanadium Catalysis
作者:Jinglei Yang、Yun-Dong Wu、Maoping Pu
DOI:10.1021/acs.joc.3c00414
日期:2023.6.2
α-Triaryl amines have been used as pharmaceuticals and pharmaceutical intermediates for antifungal and anticancer applications. Current methods to synthesize such compounds require at least two steps, and no directamination of tertiary alcohols has been reported. Herein, we disclose efficient catalytic conditions for the directamination of α-triaryl alcohols to access α-triaryl amines. VO(OiPr)3
α-三芳基胺已被用作抗真菌和抗癌应用的药物和药物中间体。目前合成此类化合物的方法至少需要两步,并且没有报道过直接胺化叔醇。在此,我们公开了直接胺化 α-三芳基醇以获得 α-三芳基胺的有效催化条件。VO(O i Pr) 3,一种市售试剂,已被确定为几种α-三芳基醇直接胺化的有效催化剂。这个过程是可扩展的,正如克级合成所证明的那样,反应在低至 0.01 mol% 的催化剂负载下仍然有效,周转数达到 3900。此外,包括克霉唑和氟霉唑在内的商业药物已成功快速制备,有效地使用这种新开发的方法。